A new pill for treating dementia is delivering promising “topline” results in early-stage clinical trials, according to a recent press release by its makers.

The treatment, called VES001 after its developer Vesper Bio, is designed to tackle frontotemporal dementia (FTD) – the most common type of dementia in the under-60s.

In a two-part preliminary safety trial at two medical centres in the Netherlands and the UK, VES001 was given to people showing no signs of FTD, including six volunteers with an increased genetic risk for the condition.